SURROGATE END POINT FOR PROSTATE CANCER SPECIFIC MORTALITY IN PATIENTS WITH NONMETASTATIC HORMONE REFRACTORY PROSTATE CANCER

These data provide evidence to support PSA velocity greater than 1.5 ng/ml yearly as a surrogate end point for PCSM in patients with nonmetastatic, hormone refractory prostate cancer. Enrolling these men onto clinical trials evaluating the impact of chemotherapy on time to bone metastases and PCSM is warranted.